Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 19 |
| Active Pipeline (Recruiting Now) | 4 (4) |
| Completed vs Stopped Early | 8 / 7 (36.8%) |
| Median Closed Actual Enrollment | 85 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University of Colorado Anschutz Medical Campus | Aurora, CO | 3 |
| Johns Hopkins Hospital and Kimmel Cancer Center | Baltimore, MD | 3 |
| Emory Winship Cancer Institute | Atlanta, GA | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07453888 | Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) | Phase III | RECRUITING |
| NCT07395232 | An Efficacy and Safety Study of DFL24498 in the Treatment of AKC | Phase III | RECRUITING |
| NCT07519902 | An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED | Phase III | RECRUITING |
| NCT04628481 | A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function | Phase II | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the Dompé Farmaceutici S.p.A Interactive Dossier, benchmark peers in Ophthalmology and Sensory, or review the Healthcare Price & Patent Cliff Crosswalk.